Ernexa Therapeutics Inc. Capital Expenditures Incurred but Not yet Paid
Ernexa Therapeutics Inc. (ERNA) reported Capital Expenditures Incurred but Not yet Paid of $18.00 thousand for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-13.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2024-08-13
- Ernexa Therapeutics Inc. capital expenditures incurred but not yet paid for the quarter ending 2024-06-30 was -$261.00K.
- Ernexa Therapeutics Inc. capital expenditures incurred but not yet paid for the quarter ending 2024-03-31 was $279.00K.
- Ernexa Therapeutics Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-03-31 was $0.00.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month |
|---|---|---|
| 2024-06-30 | -$261.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $18.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $279.00K 10-Q · filed 2024-05-14 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |